Skip to main content

Advertisement

Table 2 Baseline characteristics

From: Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry

  Use following csDMARD-IR Use following first bDMARD-IR
  Abatacept TNFi p value Abatacept TNFi p value
n 92 613 105 212
Age, years 49.3 (13.6) 47.3 (13.2) 0.1871 45.9 (14.4) 45.5 (13.0) 0.8197
Disease duration, years 7.0 (7.8) 6.8 (7.7) 0.7980 12.1 (10.4) 10.0 (8.8) 0.0660
Female, n (%) 71 (77.2) 476 (77.7) 0.8940 84 (80.0) 156 (73.6) 0.2655
Concomitant medication use, n (%)
 csDMARDs 87 (94.6) 567 (92.5) 1.0000 87 (82.9) 174 (82.1) 1.0000
 MTX 69 (75.0) 466 (76.0) 0.7955 69 (65.7) 142 (67.0) 0.8994
 HCQ 72 (78.3) 350 (57.1) < 0.0001 43 (41.0) 72 (34.0) 0.2640
 SSZ 11 (12.0) 45 (7.3) 0.1455 9 (8.6) 10 (4.7) 0.2095
 LEF 7 (7.6) 54 (8.8) 0.8434 7 (6.7) 16 (7.5) 1.0000
 Corticosteroids 45 (48.9) 282 (46.0) 0.6542 73 (69.5) 93 (43.9) < 0.0001
  Number of oral corticosteroid prescriptions per 100 person-years of treatment 81.24 44.02   99.03 76.23  
 TNFi used, n (%) N/A    N/A   
  Adalimumab   146 (23.8)    58 (27.4)  
  Certolizumab   62 (10.1)    27 (12.7)  
  Etanercept   239 (39.0)    69 (32.5)  
  Golimumab   105 (17.1)    29 (13.7)  
  Infliximab (Remicade)   60 (9.8)    26 (12.3)  
  Infliximab (Inflectra)   1 (0.2)    3 (1.4)  
Comorbidities
 Age-adjusted CCI 2.8 (1.4) 2.4 (1.3) 0.2403 2.9 (1.8) 2.6 (1.5) 0.2228
 Hyperlipidemia, n (%) 28 (30.4) 193 (31.5) 0.9044 42 (40.0) 75 (35.4) 0.4589
 Hyperglycemia, n (%) 13 (14.1) 82 (13.4) 0.8699 11 (10.5) 32 (15.1) 0.2987
 Hypertension, n (%) 37 (40.2) 290 (47.3) 0.2187 58 (55.2) 110 (51.9) 0.6329
 COPD, n (%) 37 (40.2) 194 (31.6) 0.1211 43 (41.0) 76 (35.8) 0.3905
 CVD, n (%) 11 (12.0) 75 (12.2) 1.0000 19 (18.1) 37 (17.5) 0.8769
 Charlson Comorbidity Index 1.4 (0.9) 1.2 (0.7) 0.0039 1.4 (1.2) 1.3 (0.8) 0.59
RF+, n (%) 69 (75.0) 424 (69.2) 0.2680 73 (69.5) 141 (66.5) 0.7020
ACPA+, n (%) 56 (60.9) 358 (58.4) 1.0000 55 (52.4) 107 (50.5) 1.0000
ESR, mm/h 18.7 (16.0) 24.5 (19.8) 0.0080 21.9 (19.2) 24.8 (20.8) 0.3164
CRP, mg/L 14.30 (20.20) 12.90 (20.40) 0.5875 16.30 (23.40) 11.80 (19.40) 0.1226
Patient-reported outcomes
 Patient global, VAS 0–10 5.6 (2.4) 4.8 (2.8) 0.0430 5.2 (2.7) 4.4 (2.9) 0.0324
 Patient pain, VAS 0–10 6.1 (2.6) 5.3 (3.0) 0.0401 5.7 (3.0) 5.0 (3.1) 0.1157
 Patient fatigue, VAS 0–10 5.8 (2.8) 4.7 (3.2) 0.0099 5.7 (2.8) 4.8 (3.3) 0.0597
 Morning stiffness, min 155.0 (308.3) 120.9 (274.1) 0.3676 127.3 (294.7) 93.0 (244.5) 0.3597
 HAQ 1.31 (0.61) 1.24 (0.60) 0.3661 1.51 (0.60) 1.18 (0.66) 0.0006
Physician global, VAS 0–10 4.8 (2.7) 4.0 (2.6) 0.0370 4.0 (2.6) 3.4 (2.6) 0.2256
Swollen joint count, 0–28 8.5 (5.2) 7.4 (5.3) 0.1409 7.7 (5.3) 6.5 (6.0) 0.1755
Tender joint count, 0–28 6.8 (6.4) 6.6 (5.7) 0.8451 7.3 (6.1) 5.4 (5.9) 0.0481
Disease activity measures
 CDAI 26.3 (12.7) 23.5 (11.7) 0.1416 24.8 (11.0) 18.8 (12.5) 0.0069
 SDAI 28.6 (13.1) 24.7 (12.0) 0.0639 26.3 (11.7) 20.4 (12.6) 0.0140
 DAS28-4, ESR 4.8 (1.3) 4.7 (1.3) 0.7557 4.8 (1.2) 4.5 (1.4) 0.3621
  1. Data are mean (SD), unless stated otherwise
  2. ACPA anti-citrullinated protein antibody, bDMARD biologic disease-modifying antirheumatic drug, CCI Charlson Comorbidity Index, CDAI Clinical Disease Activity Index, COPD chronic obstructive pulmonary disease, CRP C-reactive protein, csDMARD conventional synthetic disease-modifying antirheumatic drug, CVD cardiovascular disease, DAS28-4 disease activity score in 28 joints (four variables), ESR erythrocyte sedimentation rate, HAQ Health Assessment Questionnaire, HCQ hydroxychloroquine, IR inadequate response, LEF leflunomide, MTX methotrexate, RF rheumatoid factor, SDAI Simplified Disease Activity Index, SSZ sulfasalazine, TNFi tumor necrosis factor inhibitor, VAS visual analog scale